Vericel Corporation (VCEL)
VCEL Stock Price Chart
Explore Vericel Corporation interactive price chart. Choose custom timeframes to analyze VCEL price movements and trends.
VCEL Company Profile
Discover essential business fundamentals and corporate details for Vericel Corporation (VCEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Feb 1997
Employees
357.00
Website
https://vcel.comCEO
Dominick C. Colangelo
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Financial Timeline
Browse a chronological timeline of Vericel Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.02.
Earnings released on 31 Jul 2025
EPS came in at -$0.01 surpassing the estimated -$0.04 by +75.00%, while revenue for the quarter reached $63.24M , missing expectations by -2.06%.
Earnings released on 8 May 2025
EPS came in at -$0.23 falling short of the estimated -$0.09 by -155.56%, while revenue for the quarter reached $52.60M , missing expectations by -18.84%.
Earnings released on 27 Feb 2025
EPS came in at $0.38 surpassing the estimated $0.31 by +22.58%, while revenue for the quarter reached $75.38M , beating expectations by +29.69%.
Earnings released on 7 Nov 2024
EPS came in at -$0.02 surpassing the estimated -$0.05 by +60.00%, while revenue for the quarter reached $57.91M , missing expectations by -25.73%.
Earnings released on 1 Aug 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $52.66M , missing expectations by -4.56%.
Earnings released on 8 May 2024
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%, while revenue for the quarter reached $51.28M , beating expectations by +4.51%.
Earnings released on 29 Feb 2024
EPS came in at $0.26 surpassing the estimated $0.17 by +52.94%, while revenue for the quarter reached $65.00M , beating expectations by +1.67%.
Earnings released on 8 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $45.58M , beating expectations by +0.95%.
Earnings released on 2 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $45.92M , beating expectations by +2.09%.
Earnings released on 10 May 2023
EPS came in at -$0.16 falling short of the estimated -$0.13 by -23.08%, while revenue for the quarter reached $41.02M , beating expectations by +8.31%.
Earnings released on 23 Feb 2023
EPS came in at $0.12 surpassing the estimated $0.04 by +238.98%, while revenue for the quarter reached $52.69M , missing expectations by -0.35%.
Earnings released on 9 Nov 2022
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%, while revenue for the quarter reached $38.55M , missing expectations by -3.39%.
Earnings released on 3 Aug 2022
EPS came in at -$0.19 falling short of the estimated -$0.13 by -46.15%, while revenue for the quarter reached $37.05M , missing expectations by -3.39%.
Earnings released on 4 May 2022
EPS came in at -$0.15 matching the estimated -$0.15, while revenue for the quarter reached $36.07M , beating expectations by +5.16%.
Earnings released on 24 Feb 2022
EPS came in at $0.09 falling short of the estimated $0.14 by -35.71%, while revenue for the quarter reached $47.59M , missing expectations by -2.86%.
Earnings released on 9 Nov 2021
EPS came in at -$0.11 falling short of the estimated -$0.03 by -305.31%, while revenue for the quarter reached $34.51M , missing expectations by -10.61%.
Earnings released on 4 Aug 2021
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $39.52M , beating expectations by +7.77%.
Earnings released on 5 May 2021
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $34.57M , beating expectations by +7.74%.
Earnings released on 24 Feb 2021
EPS came in at $0.25 surpassing the estimated $0.20 by +25.00%, while revenue for the quarter reached $45.23M , beating expectations by +33.33%.
Earnings released on 5 Nov 2020
EPS came in at $0.08 surpassing the estimated $0.01 by +524.02%, while revenue for the quarter reached $32.26M , beating expectations by +300.00%.
VCEL Stock Performance
Access detailed VCEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.